Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 5Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neuroblastoma 3Triple Negative Breast Neoplasms 2Melanoma 2Unilateral Breast Neoplasms 1Resectable Esophageal Cancer 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × Colony-Stimulating Factors × Clear all
NCT01134614 2026-05-29

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
245 enrolled 8 charts
Dermatologic

Melanoma

NCT02339571 2026-05-29

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡